Plasma biochemical markers of bone remodeling in patients with renal insufficiency

Journal of Clinical Ligand Assay

Volumn 21, Issue 2, 1998, Pages 159-170

  Ureña, Pablo ^a  

^a Clinique de l'Orangerie Aubervilliers   (France)

Author keywords

Bone Specific Alkaline Phosphatase; Chronic Renal Failure; Cross Linked Collagen Molecules; Hemodialysis; Renal Osteodystrophy

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; OSTEOCALCIN; PROCOLLAGEN; PYRIDINOLINE;

ARTICLE; BLOOD LEVEL; BONE TURNOVER; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; HUMAN; KIDNEY FAILURE; RENAL OSTEODYSTROPHY;

EID: 0032465207     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (150)

1. Baron R: Anatomy and ultrastructure of bone, in Favus MJ (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Second Edition. New York, Raven Press, Ltd., 1993, pp 3-9.
2. Termine J: Bone matrix proteins and the mineralization process, in Favus MI (ed): Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, Second Edition. New York, Raven Press, Ltd., 1993, pp 21-25.
3. DeVernejoul MC, Kuntz D, Miravet L, et al: Bone histomorphometry in hemodialysed patients. Metab Bone Dis & Rel Res 1981;3:175-179.
4. Gagné ER, Ureña P, Leite-Silva S, et al: Short and long-term efficacy of total parathyroidectomy with immediate autografting compared with subtotal parathyroidectomy in hemodialysis patients. J Am Soc Nephrol 1992;3:1008-1017.
5. Hercz G, Pei Y, Greenwood C, et al: Aplastic osteodystrophy without aluminum: The role of "suppressed" parathyroid function. Kidney Int 1993;44:860-866.
6. Onishi S, Andress D, Maloney N, et al: Beta2-microglobulin deposition in bone in chronic renal failure. Kidney Int 1991;39:990-995.
7. Goodman WG, Ramirez JA, Belin TR, et al: Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994;46:1160-1166.
8. Mathias R, Salusky I, Harman W, et al: Renal bone disease in pediatric and young adult patients on hemodialysis in a children's hospital. J Am Soc Nephrol 1993;3:1938-1946.
9. Pei Y, Hercz G, Greenwood C, et al: Risk factors for renal osteodystrophy: A multivariantan alysis. J Bone Min Res 1995;10(1):149-156.
10. Zins B, Petitelerc C, Basile C, et al: Tumoral calcinosis in hemodialysis patients: Role of aluminum intoxication. Nephron 1992;60:260-267.
11. Massari P: Disorders of bone and mineral metabolism after renal transplantation. Kidney Int 1997;52:1412-1421.
12. Parfitt AM, Drezner MK, Glorieux FH, et al: Bone histomorphometry: Standardization of nomenclature, symbols, and units. J Bone Min Res 1987;2(6):595-610.
13. Hodsman AB, Sherrard DJ, Wong EGC, et al: Vitamin-D-resistant osteomalacia in hemodialysis patients lacking secondary hyperparathyroidism. Annals Int Med 1981;94:629-637.
14. Brossard J, Cloutier M, Roy L, et al: Accumulation of a non-(1-84) molecular form of parathyroid hormone (PTH) detected by intact PTH assay in renal failure: Importance in the interpretation of PTH values. J Clin Endocrinol Metab 1996;81:3923-3929.
15. Harris H: The human alkaline phosphatases: What we know and what we don't know. Clin Chim Acta 1989;180:177-188.
16. Seargeant LE, Stinson RA: Evidence that three structural genes code for human alkaline phosphatase. Nature 1979;281:152-154.
17. Weiss MJ, Henthorn PS, Lafferty MA, et al: Isolation and characterization of a cDNA encoding a human liver/bone/kidney-type alkaline phosphatase. Proc Natl Acad Sci USA 1986;84:7182-7186.
18. Goldstein DJ, Rogers C, Harris H: A search for trace expression of placental-like alkaline phosphatase in non-malignant human tissues: Demonstration of its occurrence in lung, cervix, testis, and thymus. Clin Chim Acta 1982;125:63-75.
19. Yoon K, Golub E, Rodan G: Akaline phosphatase cDNA transfected cells promote calcium and phosphorus deposition. Connect Tissue Res 1989;22:17-25.
20. Moss DW, Whitby LG: A simplified heat inactivation method for investigating alkaline phosphatase isoenzymes in serum. Clin Chim Acta 1975;61:63-71.
21. Moss DW: Alkaline phosphatase isoenzymes. Clin Chem 1982;28:2007-2016.
22. Garrido JC, Aguayo FJ, Moreno CA: Comparison of three bone alkaline phosphatase quantification methods in patients with increased alkaline phosphatase activities. Clin Chem 1992;38:1165-1166.
23. Gonchoroff DG, Branum EL, Cedel SL, et al: Clinical evaluation of high-performance affinity chromatography for the separation of bone and liver alkaline phosphatase isoenzymes. Clin Chim Acta 1991;199:43-50.
24. Magnusson P, Hiager A, Larsson L: Serum osteocalcin and bone and liver alkaline phosphatase isoforms in healthy children and adolescents. Pediatr Res 1995;38:955-961.
25. Duda RJ, O'Brien JF, Katzmann JA, et al: Concurrent assays of circulating bone Gla protein and bone alkaline phosphatase: Effect of sex, age and metabolic bone disease. J Clin Endocrinol Metab 1988;66:951-957.
26. Hill C, Wolfert R: The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase. Clin Chim Acta 1989;186:315-320.
27. Garnera P, Delmas PD: Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-1053.
28. Gomez B, Ardakani S, Ju J, et al: Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clin Chem 1995;41:1560-1566.
29. Seabrook R, Baileys E, Price C, et al: The distinction of bone and liver isoenzymes of alkaline phosphatase in serum using a monoclonal antibody. Clin Chim Acta 1988;172:261-266.
30. Machu-Prestaux N, Brazier M, VanHoof V, et al: Evaluation de la phosphatase alcaline osseuse sérique au cours des affections m_taboliques de l'os. Immunoanal Biol Spéc 1996;11:259-267.
31. Salusky IB, Ramirez JA, Oppenheim W, et al: Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/ CCPD. Kidney Int 1994;45:253-258.
32. Couttenye MM, D'Haese PC, VanHoof VO, et al: Bone alkaline phosphatase (BAP) compared to PTH in the diagnosis of adynamic bone disease (ABD). Nephrol Dial Transplant 1994;9:905 (Abstract).
33. Ureña P, Prieur P, Pétrover M: Phosphatase alcaline d'origine osseuse chez les patients hémodialysés. La Presse Médicale 1996;25:1320-1325.
34. Ureña P, Prieur P, Pétrover M: Calcitriol may directly suppress bone turnover. Nephron 1996;75:116-117.
35. Ureña P, Hruby M, Ferreira A, et al: Plasma total versus bone alkaline phosphatase as marker of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996;7:506-512.
36. Jarava C, Armas J, Salgueira M, et al: Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996;11(Suppl. 3):43-46.
37. Garcia R, Miguel A, Alonso J, et al: Estudio comparative del isoenzima oseo de la fosfatasa alcalina con otros marcadores del remodelado oseo. Nefrologia 1994;14:322-328.
38. Withold W, Friedrich W, Degenhardt S: Serum bone alkaline phosphatase is superior to plasma levels of bone matrix proteins for assessment of bone metabolism in patients receiving renal transplants. Clin Chim Acta 1997;261:105-115.
39. England T, Samsoondar J, Maw G: Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase. Clin Biochem 1994;27:187-189.
40. Couttenye MM, D'Haese PC, Deng JT, et al: High prevalence of adynamic bone disease diagnosed by biochemical markers in a wide sample of the European CAPD population. Nephrol Dial Transplant 1997;12:2144-2150.
41. VanHoof V, Martin M, Blockx P, et al: Immunoradiometric method and electrophoretic system compared for quantifying bone alkaline phosphatase in serum. Clin Chem 1995;41:853-857.
42. Woitge H, Seibel M, Ziegler R: Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases. Clin Chem 1996;42:1796-1804.
43. Naik RB, Gosling P, Price CP: Comparative study of alkaline phosphatase isoenzyrnes, bone histology, and skeletal radiography in dialysis bone disease. Br Med J 1977;1:1307-1310.
44. Ureña P, Ferreira A, Kung V, et al: Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patients. J Bone Min Res 1995;10:932-939.
45. Fletcher S, Jones R, Rayner H, et al: Assessment of renal osteodystrophy in dialysis patients: Use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997;75:412-419.
46. Quarles L, Lobaugh B, Murphy G: Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia. J Clin Endocrinol Metab 1992;75:145-150.
47. Whyte M, Landt M, Ryan L, et al: Alkaline phosphatase: placental and tissue-nonspecific isoenzymes hydrolyze phosphoethanolamine, inorganic pyrophosphate, and pyridoxal 5′-phosphate. J Clin Invest 1995;95:1440-1445.
48. Hruska K, Teitelbaum S: Renal osteodystrophy. N Engl J Med 1995;333:166-174.
49. Herbelin A, Ureña P, Nguyen A, et al: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int 1991;39:954-960.
50. Kyeyune-Nyombi E, Nicolas V, Strong D, et al: Paradoxical effects of phosphate to directly regulate the level of skeletal alkaline phosphatase activity in human osteosarcoma (SaOS-2) cells and inversely regulate the level of alkaline phosphatase mRNA. Calcif Tissue Int 1995;56:154-159.
51. Liang C, Barnes J: Renal expression of osteopontin and alkaline phosphatase correlates with BUN levels in aged rats. Am J Physiol 1995;269:F398-F404.
52. Marie P, Lomri A, DeVemejoul M, et al: Relationship between histomorphometric features of bone formation and bone cell characterization in vitro in renal osteodystrophy. J Clin Endocrinol Metab 1989;69:1166-1173.
53. Ureña P, Kubrusly M, Mannstadt M, et al: The renal PTH/PTHrP receptor is down-regulated in rats with chronic renal failure. Kidney Int 1994;45:605-611.
54. Fedde K, Michell M, Henthorn P, et al: Aberrant properties of alkaline phosphatase in patient fibroblasts correlate with clinical expressivity in severe forms of hypophosphatasia. J Clin Endocrinol Metab 1996;81:2587-2594.
55. Yamaguchi T, Hattori S, Nakai M, et al: A study on the biological significance of midregion and intact parathyroid hormone in hemodialysis patients. Endocrine Journal 1997;44:289-297.
56. Pahl M, Jara A, Bover J, et al: Studies in a hemodialysis patient indicating that calcitriol may have a direct suppressive effect on bone. Nephron 1995;71:218-223.
57. Parfitt A: Serum markers of bone formation in parenteral nutrition patients. Calcif Tissue Int 1991;49:143-145.
58. Deftos L: Bone protein and peptide assays in the diagnosis and management of skeletal disease. Clin Chem 1991;37:1143-1148.
59. Delmas P: Biochemical markers of bone turnover: methodology and clinical use in osteoporosis. Am J Med 1991;91:169-174.
60. Nakao M, Nishiuchi Y, Nakata M, et al: Synthesis of human osteocalcins: Gamma-carboxyglutamic acid at position 17 is essential for a calcium-dependent conformational transition. Pept Res 1994;7:171-174.
61. Koshihara Y, Hoshi K: Vitamin K2 enhances osteocalcin accumulation in the extracellular matrix of human osteoblasts in vitro. J Bone Min Res 1997;12:431-438.
62. Kohlmeier M, Saupe J, Shearer M, et al: Bone fracture risk in hemodialysis patients is related to apolipoprotein E (apoE) genotype, a modulator of vitamin K status, in Papapoulos S (ed): Osteoporosis. New York, Elsevier Science B.V., 1996, pp 155-159.
63. Kohlmeier M, Saupe J, Shearer M, et al: Bone health of adult hemodialysis patients is related to vitamin K status. Kidney Int 1997;51:1218-1221.
64. Szulc P, Chapuy M, Meunier P, et al: Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture: A three year follow-up study. Bone 1996;18:487-488.
65. Vermeer C, Jie K, Knapen M: Role of vitamin K in bone metabolism. Annu Rev Nutr 1995;15:1-22.
66. Shiraki M, Shiraki Y, Aoki C, et al: Association of bone mineral density with apolipoprotein E phenotype. J Bone Min Res 1997;12:1438-1445.
67. Zhang R, Ducy P, Karsenty G: 1,25-dihydroxyvitamin D3 inhibits osteocalcin expression in mouse through an indirect mechanism. J Biol Chem 1997;272:110-116.
68. Novak J, Hayes J, Nishimoto S: Plasmin-mediated proteolysis of osteocalcin. J Bone Min Res 1997;12:1035-1042.
69. Broulik P, Hruby M: Acute effects of hemodialysis on circulating parathormone, osteocalcin and phosphatase in patients with chronic renal failure. Cas Lek Cesk 1993;132:681-683.
70. Ducy P, Desbois C, Boyce B, et al: Increased bone formation in osteocalcin-deflcient mice. Nature 1996;382:448-452.
71. Kronenberg H: Parathyroid hormone and osteocalcin - when friends become strangers. Endocrinology 1997;138:3083-3084 (Editorial).
72. Yu X, Chandrasekhar S: Parathyroid hormone (PTH 1-34) regulation of rat osteocalcin gene transcription. Endocrinology 1997;138:3085-3092.
73. Bataille R, Delmas P, Sany J: Serum bone gla-protein in multiple myeloma. Cancer 1987;59:329-334.
74. Brown J, Delmas P, Malaval L, et al: Serum bone gla-protein: A specific marker for bone formation in postmenopausal osteoporosis. Lancet 1984;1:1091-1093.
75. Deftos L, Parthemore J, Price P: Changes in plasma bone gla protein during treatment of bone disease. Calcif Tissue Int 1982;34:121-124.
76. Price P, Parthemore J, Deftos L: New biochemical marker for bone metabolism: Measurement by radioimmunoassay of bone gla protein in the plasma of normal subjects and patients with bone disease. J Clin Invest 1980;66:878-883.
77. Douglas A, Miller M, Reid D, et al: Seasonal differences in biochemical parameters of bone remodelling. J Clin Pathol 1996;49:284-289.
78. Tracy R, Andrianoviro A, Riggs B, et al: Comparison of monoclonal and polyclonal antibody-based immunoassays forosteocalcin: A study of sources of variation in assay results. J Bone Min Res 1990;5:451-461.
79. Gamero P, Grimaux M, Demiaux B, et al: Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay. J Bone Min Res 1992;7:1389-1398.
80. Charbon SA, Delmas PD, Malaval L, et al: Serum Bone Gla-protein in renal osteodystrophy: Comparison with bone histomorphometry. J Clin Endocrinol Metab 1986;63(4):892-897.
81. Rosenquist C, Qvist P, Bjarnason N, et al: Measurement of a more stable region of osteocalcin in serum by ELISA with two monoclonal antibodies. Clin Chem 1995;41:1439-1445.
82. Garnero P, Grimaux M, Seguin P, et al: Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro. J Bone Min Res 1994;9:255-264.
83. Diaz-Diego E, Guerrero R, DeLaPiedra C: Six osteocalcin assays compared. Clin Chem 1994;40:2071-2077.
84. Minisola S, Rosso R, Romagnoli E, et al: Serum osteocalcin and bone mineral density at various skeletal sites: A study performed with three different assays. J Lab Clin Med 1997;129:422-429.
85. Prockop DJ, Kivirikko KI, Tuderman L, et al: The biosynthesis of collagen and its disorders. N Engl J Med 1979;301(1):13-23.
86. Eyre DE, Koob TJ, VanNess KP: Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography. Anal Biochem 1984;137:380-388.
87. Eyre D: Collagen crosslinking amino acids. Methods in Enzymology 1987;144:115-139.
88. Fujimoto D, Moriguchi T, Ishida T, et al: The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun 1978;84:52-57.
89. Robins SP: Crosslinking of collagen. Biochemical Journal 1983;215:167-173.
90. Bailey AJ, Robins SP, Balian G: Biological significance of the intermolecular crosslinks of collagen. Nature 1974;251:105-109.
91. Tanzer M: Crosslinking, in Ramachandran GN, Reddi AH (eds): Biochemistry of Collagen. New York, Plenum Publishing, 1976.
92. Robins S: Turnover of collagen, in Weiss J, Jayson M (Eds): Collagen in Health and Disease. Edinburgh, Churchill Livingstone, 1982, pp 160-178.
93. Seigel RC, Fu JCC: Collagen crosslinking: Purification and substrate specificity of lysyl oxidase. J Biol Chem 1976;251:5779-5785.
94. Uebelhart D, Gineyts E, Chapuy MC, et al: Urinary excretion of pyridinium crosslinks: A new marker of bone resorption in metabolic bone disease. Bone Min 1990;8:87-96.
95. Branca F, Robins SP, Ferro-Luzzi A, et al: Bone turnover in malnourished children. Lancet 1992;340:1493-1496.
96. Robins SP, Black D, Paterson CR, et al: Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest 1991;21:310-315.
97. Robins SP, Duncan A, McLaren AM: Structural specificity of an ELISA for the collagen crosslinks, pyridinoline: Implications for the measurement of free pyridinium crosslinks as indices of bone resorption in metabolic bone disease. J Bone Min Res 1991;6:C642.
98. Kamel S, Brazier M, Neri V, et al: Multiple molecular forms of pyridinolines crosslinks excreted in human urine evaluated by chromatographic and immunoassay methods. J Bone Min Res 1995;10:1385-1392.
99. Seibel MJ, Woitge H, Scheidt-Nave C, et al: Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: Results of a pilot study. J Bone Min Res 1994;9:1433-1440.
100. Black D, Duncan A, Duncan SP: Quantitative analysis of the pyridinium crosslinks of collagen in urine using ion-paired reversed-phase high performance liquid chromatography. Anal Biochemistry 1988;169:197-203.
101. Seibel MJ, Duncan A, Robins SP: Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheurn 1989;16(7):964-970.
102. Seibel MJ, Gartenberg F, Silverberg SJ, et al: Urinary hydroxypyridinium crosslinks of collagen in primary hyperparathyroidism. J Clin Endocrinol Metab 1992;74:481-486.
103. Robins SP, Hesley R, Ju J, et al: Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Min Res 1994;9(10):1643-1649.
104. Seyedin S, Kung VT, Daniloff YN, et al: Immunoassay for urinary pyridinoline: The new marker of bone resorption. J Bone Min Res 1993;8(5):635-641.
105. Kung VT, Gomez B, Lungard R, et al: An immunoassay for the measurement of free pyridinoline in serum: A marker of bone resorption, y Bone Min Res 1993;8:S151.
106. Harvey RD, McHardy KC, Reid IW, et al: Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium crosslinks as specific urinary markers. J Clin Endocrinol Metab 1991;72:1189-1194.
107. Garnero P, Vassy V, Bertholin A, et al: Markers of bone turnover in hyperthyroidism and effects of treatment. J Clin Endocrinol Metab 1994;78:955-959.
108. Body JJ, Delmas PD: Urinary pyridinium cross-links as markers of bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol Metab 1992;74:471-475.
109. Delmas PD, Schlemmer A, Gineyts E, et al: Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on iliac crest biopsy in patients with vertebral osteoporosis. J Bone Min Res 1991;6(6):639-644.
110. Delmas PD, Gineyts E, Bertholin A, et al: Immunoassay of pyridinoline crosslink excretion in normal adults and in Paget's disease. J Bone Min Res 1993;8(5):643-648.
111. Kagebayashi Y, Samma S, Yoshida K, et al: Serum and urinary pyridinium crosslinks in patients with predialysis chronic renal failure. Nippon Jinzo Gakkai Shi 1996;38:248-253.
112. Kagebayashi Y, Samma S, Yoneda T, et al: Measurement and clinical significance of serum concentration of pyridinium crosslinks in patients with renal osteodystrophy. Nippon Jinzo Gakkai Shi 1995;37:397-403.
113. Ibrahim S, Mojiminiyi S, Barron J: Pyridinium crosslinks in patients on haemodialysis and continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 1995;10:2290-2294.
114. Ezzat S, Melmed S, Endres D, et al: Biochemical assessment of bone formation and resorption in acromegaly. J Clin Endocrinol Metab 1993;76:1452-1457.
115. Vaccaro F, Pagano A, Gioviale M, et al: Diagnostic value of pyridinolinic urinary collagen cross-links in hyperparathyroidism of kidney transplant patients. Dialysis and Transplantation 1996;25:132-163.
116. McLaren AM, Isdale AH, Whiting PH, et al: Physiological varia-tions in the urinary excretion of pyridinium crosslinks of collagen. Br J Rheumatol 1993;32:307-312.
117. Niwa T, Shiobara K, Hamada T, et al: Serum pyridinolines as specific markers of bone resorption in hemodialyzed patients. Clin Chim Acta 1995;235:33-40.
118. Allen S, Nuttleman P, Ketcham C, et al: Purification and characterization of human bone tartrate-resistant acid phosphatase. J Bone Min Res 1989;4:47-55.
119. Kraenzlin M, Lau K, Liang L, et al: Development of an immunoassay for human serum osteoclastic tartrate-resistant acid phosphatase. J Clin Endocrinol Metab 1990;71:442-451.
120. Lau K, Orishi T, Wergedal J, et al: Characterization and assay of tartrate-resistant acid phosphatase activity in serum: Potential use to assess bone resorption. Clin Chem 1987;33:458-462.
121. Ek-Rylander B, Bill P, Norgard M, et al: Cloning, sequence, and development expression of a type 5, tartrate-resistant acid phosphatase of rat bone. J Biol Chem 1991;266:24684-24689.
122. Hayman A, Jones S, Boyde A, et al: Mice lacking tartrate-resistant acid phosphatase (Acp 5) have disrupted endochondral ossification and mild osteopetrosis. Development 1996;122:3151-3162.
123. Lam K, Dannaher C, Letchford S, et al: Tartrate-resistant acid phosphatase in serum of cancer patients. Clin Chem 1984;30:457.
124. Malluche HH, Juvin R, Allen SH, et al: Serum tartrate-resistant acid phosphatase reflects osteoclastic resorption better than PTH in dialyzed patients. J Am Soc Nephrol 1991;2:337.
125. Lopez-Gavilanes E, Gonzalez-Parra E, DelaPiedra C, et al: Clinical usefulness of serum carboxyterminal propeptide of procollagen I and tartrate-resistant acid phosphatase determination to evaluate bone turnover in patients with chronic renal failure. Miner Electrolyte Metab 1994;20:259-264.
126. Scamecchia L, Minisola S, Pacitti MT, et al: Clinical usefulness of serum tartrate-resistant acid phosphatase activity determination to evaluate bone turnover. Scand J Clin Lab Invest 1991;51:517-524.
127. Stepan J, Silinkova-Malkova E, Havranek T, et al: Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 1983;133:189-200.
128. Stepan J, Lachmanova J, Strakova M, et al: Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone and Mineral 1987;3:177-183.
129. Hamdy NAT, Risteli J, Beneton MNC, et al: Serum type I procollagen peptide: A noninvasive index of bone formation in patients on hemodialysis. Nephrol Dial Transplant 1993:469.
130. Parfitt AM, Simon LS, Villanueva AR, et al: Procollagen type I carboxy-terminal extension peptide in serum as a marker of collagen biosynthesis in bone: Correlation with iliac bone formation rates and comparison with total alkaline phosphatase. J Bone Min Res 1987;2(5):427-436.
131. Coen G, Mazzaferro S, DeAntoni A, et al: Procollagen type I C-terminal extension peptide serum levels following parathyroidectomy in hyperparathyroid patients. Am J Nephrol 1994;14:106-112.
132. Coen G, Mazzaferro S, Ballanti P, et al: Procollagen type I C-terminal extension peptide in predialysis chronic renal failure. Am J Nephrol 1992;12:246-251.
133. Coen G, Ballanti P, Mazzaferro S, et al: Procollagen type I C-terminal extension peptide, PTH, and 1,25(OH)2 D3 in chronic renal failure. Bone 1993;14:415-420.
134. Hamdy NAT, Risteli J, Risteli S, et al: Serum type I procollagen peptide: A noninvasive index of bone formation in patients on hemodialysis. Nephrol Dial Transplant 1994;9:511-516.
135. Hoshino H, Kushida K, Takahashi M, et al: Short-term effect of parathyroidectomy on biochemical markers in primary and secondary hyperparathyroidism. Miner Electrolyte Metab 1997;23:93-99.
136. Ureña P, Basile C, Grateau G, et al: Short-term effects of parathyroidectomy on plasma biochemistry in chronic uremia: A prospective study. Kidney Int 1989;36:120-126.
137. Hassager C, Jensen LT, Podenphant J, et al: The carboxy-terminal pyridinoline crosslinked telopeptide of type I collagen in serum as a marker of bone resorption: The effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int 1994;54:30-33.
138. Risteli J, Elomaa I, Niemi S, et al: Radioimmunoassay for the pyridinoline crosslinked carboxy-terminal telopeptide of type I collagen: A new serum marker of bone collagen degradation. Clin Chem 1993;39(4):635-640.
139. Bonde M, Garnero P, Fledelius C, et al: Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J Bone Aim Res 1997;12:1028-1034.
140. Eriksen EF, Charles P, Melsen F, et al: Serum markers of type I collagen formation in degradation in metabolic bone disease: Correlation with bone histomorphometry. J Bone Min Res 1993;8(2):127-132.
141. Gamero P, Shih W, Gineyts E, et al: Comparison of new biochemical markers of bone turnover in late post-menopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-1700.
142. Mazzaferro S, Pasquali M, Ballanti P, et al: Diagnostic value of serum peptides of collagen synthesis and degradation in dialysis renal osteodystrophy. Nephrol Dial Transplant 1995;10:52-58.
143. Ferreira A, Ureña P, Ang K, et al: Relationship between serum β2-microglobulin, bone histology, and dialysis membranes in uraemic patients. Nephrol Dial Transplant 1995;10:1701-1707.
144. Ricco H, Ripoll E, Revilla M. et al: β2-microglobulin in postmenopausal osteoporosis. Calcif Tissue Int 1993;53:78-80.
145. Ripoll E, Anibas I, Relea P, et al: Beta-2-microglobulin in disease with high bone remodeling. Calcif Tissue Int 1995;57:272-276.
146. Zofkova I, Kancheva R, Bendlova B: Effect of 1,25(OH)2 vitamin D3 on circulating insulin-like growth factor-I and B2-microglobulin in patients with osteoporosis. Calcif Tissue Int 1997;60:236-239.
147. Takagi M, Kasayama S, Yamamoto T, et al: Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Min Res 1997;12:439-446.
148. Miyata T, Notoya K, Yoshida K, et al: Advanced glycation end products enhance osteoclast-induced bone resorption in cultured mouse unfractionated bone cells and in rats implanted subcutane-ously with devitalized boneparticles. J Am Soc Nephrol 1997;8:260-270.
149. Langub M, Nicholas N, Turner H, et al: Bone resorption and mRNA expression of IL-6 and IL-6 receptor in patients with renal osteodystrophy. Kidney Int 1996;50:515-520.
150. Seibel MJ, Woitge H, Pecherstorfer M, et al: Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. J Clin Endocrinol Metab 1996;81:3289-3294.